The cyclin-dependent kinase inhibitor Roughex is involved in mitotic exit in Drosophila

被引:31
|
作者
Foley, E [1 ]
Sprenger, F [1 ]
机构
[1] Univ Cologne, Genet Inst, D-50931 Cologne, Germany
关键词
D O I
10.1016/S0960-9822(01)00050-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Exit from mitosis is a tightly regulated event. This process has been studied in greatest detail in budding yeast, where several activities have been identified that cooperate to downregulate activity of the cyclin-dependent kinase (CDK) Cdc28 and force an exit from mitosis. Cdc28 is inactivated through proteolysis of B-type cyclins by the multisubunit ubiquitin ligase termed the anaphase promoting complex/cyclosome (APC/C) and inhibition by the cyclin-dependent kinase inhibitor (CKI) Sic1. In contrast, the only mechanism known to be essential for CDK inactivation during mitosis in higher eukaryotes is cyclin destruction. Results: We now present evidence that the Drosophila CKI Rougher (Rux) contributes to exit from mitosis, Observations of fixed and living embryos show that metaphase is significantly longer in rux mutants than in wild-type embryos. In addition, Rux overexpression is sufficient to drive cells experimentally arrested in metaphase into interphase. Furthermore, rux mutant embryos are impaired in their ability to overcome a transient metaphase arrest induced by expression of a stable cyclin A. Rux has numerous functional similarities with Sic1. While these proteins share no sequence similarity, we show that Sic1 inhibits mitotic Cdk1-cyclin complexes from Drosophila in vitro and in vivo, Conclusions: Rux inhibits Cdk1-cyclin A kinase activity during metaphase, thereby contributing to exit from mitosis, To our knowledge, this is the first mitotic function ascribed to a CKI in a multicellular organism and indicates the existence of a novel regulatory mechanism for the metaphase to anaphase transition during development.
引用
收藏
页码:151 / 160
页数:10
相关论文
共 50 条
  • [21] Rux is a cyclin-dependent kinase inhibitory (CKI) specific for mitotic cyclin-Cdk complexes
    Foley, E
    O'Farrell, PH
    Sprenger, F
    CURRENT BIOLOGY, 1999, 9 (23) : 1392 - 1402
  • [22] Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol
    Shapiro, GI
    CLINICAL CANCER RESEARCH, 2004, 10 (12) : 4270S - 4275S
  • [23] Cyclin-dependent kinase inhibitor gene polymorphisms in pituitary gigantism
    Run Yu
    Vivien Bonert
    Martha Cruz-Soto
    Shlomo Melmed
    Endocrine, 2006, 29 : 119 - 120
  • [24] Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor
    Gebbia, Vittorio
    Valerio, Maria Rosaria
    Firenze, Alberto
    Vigneri, Paolo
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (08) : 945 - 953
  • [26] Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development
    Zhai, SP
    Senderowicz, AM
    Sausville, EA
    Figg, WD
    ANNALS OF PHARMACOTHERAPY, 2002, 36 (05) : 905 - 911
  • [27] Cyclin-dependent kinase inhibitor gene polymorphisms in pituitary gigantism
    Yu, R
    Bonert, V
    Cruz-Soto, M
    Melmed, S
    ENDOCRINE, 2006, 29 (01) : 119 - 120
  • [28] Cdk pathway: Cyclin-dependent kinases and cyclin-dependent kinase inhibitors
    Gitig, DM
    Koff, A
    MOLECULAR BIOTECHNOLOGY, 2001, 19 (02) : 179 - 188
  • [29] Cdk pathway: Cyclin-dependent kinases and cyclin-dependent kinase inhibitors
    Diana M. Gitig
    Andrew Koff
    Molecular Biotechnology, 2001, 19 : 179 - 188
  • [30] Inhibitory Phosphorylation of Cyclin-Dependent Kinase 1 as a Compensatory Mechanism for Mitosis Exit
    Chow, Jeremy P. H.
    Poon, Randy Y. C.
    Ma, Hoi Tang
    MOLECULAR AND CELLULAR BIOLOGY, 2011, 31 (07) : 1478 - 1491